迷幻体验在治疗抗治疗抑郁症的 псилоцибин治疗中的作用
Guy M Goodwin1, Scott T Aaronson2, Oscar Alvarez3
1Compass Pathfinder Ltd (a subsidiary of Compass Pathways plc), London, UK.
Journal of affective disorders
|December 20, 2024
概括
псилоцибин剂量和迷幻体验强度与治疗耐药抑郁症的治疗结果相关. 这些发现表明psilocybin.
科学领域:
- 心理药理学 心理药理学
- 神经科学是一个神经科学.
- 临床心理学 临床心理学
背景情况:
- 耐治疗抑郁症 (TRD) 在精神卫生保健中构成了重大挑战.
- 在某些中发现的一种化合物psilocybin正在研究其治疗潜力.
- 了解西剂量,主观经验和治疗疗效之间的关系至关重要.
研究的目的:
- 为了研究 псилоцибин剂量,迷幻体验的强度和TRD患者的治疗结果之间的相关性.
- 探索西在治疗抑郁症中的潜在作用机制.
主要方法:
- 一次剂量为25毫克,10毫克或1毫克的COMP360西给了233名TRD参与者,并提供心理支持.
- 用五维意识改变状态 (5D-ASC) 问卷和情绪突破目录 (EBI) 来量化迷幻体验.
- 相关性分析被用来检查迷幻体验变量和抑郁症症状变化 (蒙特哥马利-阿斯伯格抑郁症评分表 (MADRS)) 在药物后3周之间的关系.
主要成果:
- 迷幻效应的强度显示出与剂量相关的趋势,不同剂量的psilocybin在得分上有相当大的重叠.
- 抑郁反应与迷幻体验的特定方面有显著的相关性.
- 在25毫克剂量下,海洋无界度和视觉重组 (5D-ASC) 的维度和EBI得分与第3周的MADRS得分显示出最强的负相关性,表明这些经验的强度与更大的抑郁症减少有关.
结论:
- 迷幻体验的质量和强度似乎是 psilocybin 作用的显著药理学指标.
- 相关性表明psilocybin在治疗抑郁症方面具有特定的作用机制.
- 研究结果表明,单次口服 псилоцибин剂量存在潜在的剂量反应现象,尽管在更大的研究中需要进一步复制.
相关概念视频
01:27Hallucinogens and Psychedelics
156
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
156
01:30Electroconvulsive Therapy
25
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
25
01:22CNS Stimulants: Psychedelic Agents
124
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
124
01:29Psychodynamic Therapy
56
Psychodynamic therapies emphasize the exploration of unconscious processes and early childhood experiences as fundamental contributors to psychological difficulties. These therapies, deeply rooted in Freud's psychoanalytic theory, aim to uncover and resolve unconscious conflicts, granting individuals insights that promote emotional and behavioral healing. Contemporary psychodynamic approaches have evolved, integrating a broader range of influences and methodologies while still valuing the...
56
01:54The Placebo Effect
6.1K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.1K
01:23Antidepressant Drugs: MAOIs and Other Agents
194
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
194